Heart Health Hypertension, guidelines, therapies- use of ACE inhibitors, angiotensin receptor blockers (ARB), calcium channel blockers and diuretics with or without β-blockers, combination therapy, barriers​. Infographics Hypertension, Dyslipidaemia, and Cardiometabolic Disease – Insights on Pathophysiology, Interplay, and Therapeutic Management VIEW INFOGRAPHIC Articles Association between cardiometabolic index and hypertension among US adults from NHANES 1999–2020 READ MORE Nutrition and Lifestyle Interventions in Managing Dyslipidemia and Cardiometabolic Risk READ MORE Improving Therapeutic Adherence and Reducing Therapeutic Inertia in the Management of People with Cardiometabolic Diseases: A Call-to-Action from the Middle East READ MORE Reducing the global prevalence of cardiometabolic risk factors: a bet worth winning READ MORE Unique cardiometabolic factors in women that contribute to modified cardiovascular disease risk READ MORE Tackling cardiometabolic disease in southeast Asia: local research to inform local practice READ MORE The synergistic effect of obesity and dyslipidemia on hypertension: results from the STEPS survey READ MORE Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024 READ MORE Management of Hypertension in the Asia-Pacific Region: A Structured Review READ MORE Hypertension and Dyslipidemia: the Two Partners in Endothelium-Related Crime READ MORE Asia-Pacific Investigators and Asian Enrollment in Cardiometabolic Trials: Insights From Publications Between 2011 and 2020 READ MORE Asian Pacific Society of Cardiology Consensus Recommendations on Dyslipidaemia READ MORE How would you rate this content? Submit Rating
